Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Th

- New Clinical Data on ARO-RAGE Show Continued Dose Response with Single Inhaled Dose of 184 mg Achieving Mean Knockdown of 90% and Max of 95%


- Adipose Delivery Platform Achieved Single Dose... | June 1, 2023

Related Keywords

Miami , Florida , United States , Christopher Anzalone , Kira Goldberg , Matthias Salathe , Michael Benatar , Nasdaq , Research Development Rd Day , Langone Medical Center , Md University Of Kansas Medical Center , Arrowhead Pharmaceuticals Inc , Arrowhead Pharmaceuticals , Miami Miller School , Kansas Medical Center , Medical Center , Harbor Statement , Private Securities Litigation Reform Act , Nc Stock Exchange , News , Information , Press Release , Few , Linical , Data , N , Show , Ontinued , Nose , Response , Ith , Single , Inhaled , F , 84 , G , Chieving , Sean , Knockdown , End , Tax , Adipose , Delivery , Platform , Chieved , Ingle Arwr Us04280a1007 ,